IL158121A - 5-membered heterocycles, pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments - Google Patents
5-membered heterocycles, pharmaceutical compositions comprising them and uses thereof for the manufacture of medicamentsInfo
- Publication number
- IL158121A IL158121A IL158121A IL15812103A IL158121A IL 158121 A IL158121 A IL 158121A IL 158121 A IL158121 A IL 158121A IL 15812103 A IL15812103 A IL 15812103A IL 158121 A IL158121 A IL 158121A
- Authority
- IL
- Israel
- Prior art keywords
- butyl
- thiazol
- methyl
- imidazol
- ethylcarbamate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Claims (1)
1. I l l Claims 1. Compound characterized in that it is chosen from the following compounds: - 2,6-di½ri-butyl-4-{ 2-[2-(methylamino)ethyl]-l,3-thiazol-4-yl}phenol; - 2,6-dite/-/-butyl-4-[4-(hydroxymethyl)-l,3-oxazol-2-yl]phenol; - 2-[l -(methylaniino)ethyl]-l ,3-thiazol-4-yl}phenol; - 2,6-diter -butyl-4-[2-(methoxymethyl)-l,3-thiazol-4-yl]phenol; - 2,6-dite/ -butyl-4-{4-[(methylamino)methyl]-l ,3-oxazol-2-yl }phenol; - N-{ [4-(3,5-dir.?rt-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methyl}acetamide; - ethyl [4-(3,5-diter/-butyl-4-hydroxyphenyl)- 1 ,3-thiazol-2-yl]methylcarbamate; - 2,6-di½r butyl-4-[2-(mo holin-4-ylmethyl)-l,3-thiazol-4-yl]phenol; - 2,6-dirert-butyl-4-[2-(thiomorpholin-4-ylmethyl)-l ,3-thiazol-4-yl]phenol; - 4-[2-(anilinomethyl)-l,3-thiazol-4-yl]-2,6-di½rt-butylphenol; - 2,6-dite/ -butyl-4-(2-{ [[2-(dimethylamino)ethyl](methyl)amino]methyl}-l,3-thiazol-4-yl)phenol; - 2,6-di/e -butyl-4-{5-methyl-2-[(methylamino)methyl]-l,3-thiazol-4-yl}phenol; - l -[4-(10H-phenothiazin-2-yl)-l ,3-thiazol-2-yl]methanamine; - N- { [4-(3,5-di/er -butyl-4-hydroxyphenyl)- 1 ,3-thiazol-2-yl]methyl } -N-methyl acetami de ; - l -[4-(3,5-dir 3. Pharmaceutical composition containing, as active ingredient, at least one of the compounds according to claim 2. 4. Use of a compound characterized in that it is chosen from the following compounds: - 2,6-di/err-butyl-4-{2-[2-(methylamino)ethyl]-l ,3-thiazol-4-yl }phenol; - 2,6-di/err-butyl-4-[4-(hydroxymethyl)-l,3-oxazol-2-yl]phenol; - 2,6-difer/-butyl-4- { 2-[ 1 -(methylamino)ethyl]- 1 ,3-thiazol-4-yl }phenol; - 2,6-di/err-butyl-4-[2-(methoxymethyl)-l,3-thiazol-4-yl]phenol; - 2,6-di/m-butyl-4- { 4- [(methylamino)methyl] - 1 ,3-oxazol-2-yl } phenol ; - N-{ [4-(3,5-di/eri-butyl-4-hydroxyphenyl)-l ,3-thiazol-2-yl]methyl}acetamide; - ethyl [4-(3,5-ditert-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methylcarbamate; - 2,6-di½rr-butyl-4-[2-(morpholin-4-ylmethyl)-l,3-thiazol-4-yl]phenol; - 2,6-di/ert-butyl-4-[2-(thiomo holin-4-ylmethyl)-l,3-thiazol-4-yl]phenol; - 4-[2-(anilinomethyl)-l,3-thiazol-4-yl]-2,6-di½rt-butylphenol; - 2,6-dir -butyl-4-(2-{ [[2-(dimethylarruno)ethyl](methyl)amino]methyl}-l,3-thiazol-4-yl)phenol; - 2,6-direrr-butyl-4-{ 5-methyl-2-[(methylamino)methyl]-l,3-thiazol-4-yl}phenol; - 1 -[4-( 10H-phenothiazin-2-yl)- 1 ,3-thiazol-2-yl]methanamine; - N- { [4-(3,5-direrf-butyl-4-hydroxyphenyl)- 1 ,3-thiazol-2-yl]methyl } -N-methylacetamide; - 1 -[4-(3,5-diterr-butyl-4-methoxyphenyl)- l,3-thiazol-2-yl]-N-methylmethanamine; - 2,6-di/err-butyl-4-{2-[(ethylamino)methyl]-l,3-thiazol-4-yl}phenol; - 2,6-dirm-butyl-4-{ 2-[(4-phenylpiperazin-l -yl)methyl]-l,3-thiazol-4-yl }phenol; - 2,6-dirm-butyl-4- { 2-[(4-methyl- 1 ,4 -diazepan- 1 -yl)methyl]- 1 ,3-thiazol-4-yl Jphenol; - N- { 1 -[4-(4-anilinophenyl)- 1 ,3-thiazol-2-yl]ethyl } -N-methylamine; - 2,6-di½r/-butyl-4-{ 2-[(isopropylamino)methyl]-l,3-thiazol-4-yl}phenol; - 2,6-ditert-butyl-4-{2-[(cyclohexylamino)methyl]-l ,3-thiazol-4-yl}phenol; - 2,6-direrr-butyl-4-{2-[(4-isopropylpiperazin-l-yl)methyl]-l,3-thiazol-4-yl }phenol; - N-methyl-1 -[4-(10H-phenothiazin-2-yl)-l,3-thiazol-2-yl]ethanamine; - 2,6-diri?r/-butyl-4-{2-[(4-ethylpiperazin-l-yl)methyl]-l,3-thiazol-4-yl }phenol; - N-{ [4-(4-anilinophenyl)-l ,3-thiazol-2-yl]methyl}-N-ethylamine; - N-{ [4-(10H-phenothiazin-2-yl)-l ,3-thiazol-2-yl]methyl }ethanamine; - 2,6-direr/-butyl-4-(2- { [4-(dimethylamino)piperidin- 1 -yl]methyl } - 1 ,3-thiazol-4-yl)phenol; - 1 - { [4-(3,5-di½rr-butyl-4-hydroxyphenyl)- 1 ,3-thiazol-2-yl]methyl } piped din-4-ol; - 4-methylpentyl 2-[4-(l,l '-biphenyl-4-yl)-lH-iniidazol-2-yl]ethylcarbamate; - 3,3-dimethylbutyl 2-[4-(4-pyrrolidin-l-ylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - isopentyl 2-[4-(l, -biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - hexyl 2-[4-(4'-bromo-l, r-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - benzyl 2-[4-(4-rerr-butylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - 3,3-dimethylbutyl 2-[4-( l,r-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - hexyl 2-[4-(4-pyrrolidin-l-ylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - hexyl 2-[4-(3,5-di½rt-butyl-4-hydroxyphenyl)-lH-imidazol-2-yl]ethylcarbamate; - 3,3-dimethylbutyl 2-[4-(3,5-di/m-butyl-4-hydroxyphenyl)-lH-imidazol-2-yl]ethylcarbamate; - 3,3-dimethylbutyl 2-[4-(4-methoxyphenyl)-lH-imidazol-2-yl]ethylcarbamate; - benzyl 2-[4-(3,5-dit 6. Use of one of the following compounds: - 2,6-di½rr-butyl-4-{ 2-[2-(methylamino)ethyl]-l,3-thiazol-4-yl}phenol; - 2,6-difm-butyl-4-[4-(hydroxymethyl)-l ,3-oxazol-2-yl]phenol; - 2,6-di ert-butyl-4- { 2-[ 1 -(methylamino)ethyl]- 1 ,3-thiazol-4-yl Jphenol; - 2,6-di/err-butyl-4-[2-(methoxymethyl)-l ,3-thiazol-4-yl]phenol; - 2,6-di/err-butyl-4- { 4-[(methylamino)methyl]- 1 ,3-oxazol-2-yl Jphenol; - N-{ [4-(3,5-dire/V-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methyl }acetamide; - ethyl [4-(3,5-di er/-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methylcarbamate; - 2,6-di/er butyl-4-[2-(mo holin-4-ylmethyl)-l ,3-thiazol-4-yl]phenol; - 2,6-di½rr-butyl-4-[2-(thiomo holin-4-ylmethyl)-l,3-thiazol-4-yl]phenol; - 4-[2-(anilinomethyl)-l ,3-thiazol-4-yl]-2,6-diterf-butylphenol; - 2,6-dirm-butyl-4-(2-{ [[2-(dimethylamino)ethyl](methyl)amino]methyl }-l ,3-thiazol-4-yl)phenol; - 2,6-ditert-butyl-4-{5-methyl-2-[(methylamino)methyl]-l ,3-thiazol-4-yl }phenol; - 1 -[4-( 10H-phenothiazin-2-yl)- 1 ,3-thiazol-2-yl]methanamine; - N-{ [4-(3,5-direr/-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methyl }-N-methy lacetami de ; - l -[4-(3,5-di½^butyl-4-methoxyphenyl)-l,3-thiazol-2-yl]-N-methylmethanamine; - 2,6-dirm-butyl-4-{ 2-[(ethylamino)methyl]-l ,3-thiazol-4-yl Jphenol; - 2,6-di½r/-butyl-4-{ 2-[(4-phenylpiperazin-l-yl)methyl]-l,3-thiazol-4-yl}phenol; - 2,6-di½rt-butyl-4-{2-[(4-methyl-l,4 -diazepan-l-yl)methyl]-l ,3-thiazol-4-yl Jphenol; - N- { 1 -[4-(4-anilinophenyl)- 1 ,3-thiazol-2-yl]ethyl } -N-methylamine; - 2,6-di/ 7. Use according to claim 6, characterized in that the compound used is chosen from one of the following compounds: - 2,6-di½/Y-butyl-4- { 2-[ 1 -(methylamino)ethyl] - 1 ,3-thiazol-4-yl }phenol ; - l -[4-(3,5-ditert-butyl-4-methoxyphenyl)-l,3-thiazol-2-yl]-N-methylmethanamine; - 2,6-di½r/-butyl-4-{ 2-[(ethylamino)methyl]-l,3-thiazol-4-yl Jphenol; - l-{ [4-(3,5-ditert-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methyl }piperidin-4-ol; - l-{ [4-(3,5-di-ier/-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methyl }pyrrolidin-3-ol; - l-{ [4-(3,5-di-reri-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methyl}azetidin-3-ol; - (3R)-l-{ [4-(3,5-di-tert-butyl-4-hydroxyphenyl)-l ,3-thiazol-2-yl]methyl}pyrrolidin-3-ol; - (35)-l-{ [4-(3,5-di-tert-butyl-4-hydroxyphenyl)-l ,3-thiazol-2-yl]methyl}pyrrolidin- 3- ol; - N, 2-dimethyl- 1 -[4-( 10H-phenothiazin-2-yl)- 1 ,3-thiazol-2-yl]propan- 1 -amine; and the pharmaceutically acceptable salts of the latter. 8. Use according to claim 6 or 7, characterized in that the medicament prepared is intended to treat one of the following disorders or diseases: Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depression and psychoses. 9. Use of one of the following compounds - 2,6-di rr-butyl-4- { 2-[2-(methylamino)ethyl]- 1 ,3-thiazol-4-yl Jphenol; - 2,6-dirm-butyl-4- { 2-[ 1 -(methylamino)ethyl]- 1 ,3-thiazol-4-yl Jphenol; - 2,6-direrr-butyl-4-{4-[(methylamino)methyl]-l,3-oxazol-2-yl}phenol; - 2,6-diiert-butyl-4-{5-methyl-2-[(methylamino)methyl]-l,3-thiazol-4-yl Jphenol; - l-[4-(3,5-diie^butyl-4-methoxyphenyl)-l,3-thiazol-2-yl]-N-methylmethanamine; - 2,6-ditm-butyl-4-{ 2-[(ethylamino)methyl]-l,3-thiazol-4-yl Jphenol; - 4-methylpentyl 2-[4-( 1 , 1 '-biphenyl-4-yl)- 1 H-imidazol-2-yl]ethylcarbamate; - 3,3-dimethylbutyl 2-[4-(4-pyrrolidin- 1 -ylphenyl)- 1 H-imidazol-2-yl]ethylcarbamate; - isopentyl 2-[4-(l , -biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - hexyl 2-[4-(4'-bromo-l, -biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbarnate; - benzyl 2-[4-(4-tert-butylphenyl)- lH-imidazol-2-yl]ethylcarbamate; - 3,3-dimethylbutyl 2-[4-( 1 , 1 -biphenyl-4-yl)- lH-imidazol-2-yl]ethylcarbamate; - hexyl 2-[4-(4-pyrrolidin-l -ylphenyl)- lH-imidazol-2-yl]ethylcarbamate; - hexyl 2-[4-(3,5-dite;v-butyl-4-hydroxyphenyl)-lH-imidazol-2-yl]ethylcarbamate; - hexyl 2-[4-(3,5-di½rt-butyl-4-hydroxyphenyl)-lH-imidazol-2-yl]ethylcarbamate; - 3,3-dimethylbutyl 2-[4-(4-methoxyphenyl)-lH-imidazol-2-yl]ethylcarbamate; - benzyl 2-[4-(3,5-di/e^butyl-4-hydroxyphenyl)-lH-imidazol-2-yl]ethylcarbamate; - benzyl 2-[4-(4-pyrrolidin-l-ylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - 2-phenylethyl 2-[4-(l , -biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(4'-fluoro- 1 , 1 -biphenyl-4-yl)- lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(l,l '-biphenyl-4-yl)-5-methyl-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(4'-methyl- 1 , 1 '-biphenyl-4-yl)- lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(4'-chloro-l ,r-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(2'-fluoro-l, r-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(2', 4'-difluoro-l , r-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(3'-chloro- 1 , 1 '-biphenyl-4-yl)- 1 H-imidazol-2-yl]ethylcarbamate; - butyl 2- [4-(3'-fluoro- 1 , 1 '-biphenyl-4-yl)- 1 H-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(4-isobutylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - benzyl 2-[4-(4-isobutylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(3'-chloro-4'-fluoro-l, -biphenyl-4-yl)-lH-irrddazol-2-yl]ethylcarbarnate; - butyl 2-[4-(3', 4'-dichloro-l,r-biphenyl-4-yl)-lH-irnidazol-2-yl]ethylcarbamate; - butyl 2-[4-(4-propylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(4-ethylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(4'-cyano-l,r-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(l, -biphenyl-4-yl)-5-ethyl-lH-imidazol-2-yl]ethylcarbarnate; - butyl 2-[4-(2'-chloro- 1 , 1 -biphenyl-4-yl)- lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(2', 3'-difluoro-l ,l '-biphenyl-4-yl)-lH-irnidazol-2-yl]ethylcarbarnate; - butyl 2-[4-(2'-bromo-l ,1 ,-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(3', 5'-difluoro-l, -biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbarnate; - butyl 2-[4-(2'-methoxy- 1 , 1 '-biphenyl-4-yl)- lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(3'-nitro-l, -biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbarnate; - butyl 2-[4-(2', 5'-difluoro-l,r-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(3'-methoxy- 1 , 1 '-biphenyl-4-yl)- lH-imidazol-2-yl]ethylcarbamate; or of a pharmaceutically acceptable salt of one of the latter for preparing a medicament intended to modulate the sodium channels. 10. Use according to claim 9, characterized in that the medicament prepared is intended to treat one of the following disorders or diseases: Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, migraine or pain and in particular neuropathic pain. For ftfae ApplloQR¾o Mmm com moie
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0104943A FR2823208B1 (en) | 2001-04-10 | 2001-04-10 | 5-CHAIN CHAIN HETEROCYCLE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS |
FR0201811 | 2002-02-14 | ||
PCT/FR2002/001218 WO2002083656A2 (en) | 2001-04-10 | 2002-04-09 | 5-membered heterocycles, preparation and use thereof as mao inhibitors and lipid peroxidation inhibitors, preparation thereof and use thereof as medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
IL158121A true IL158121A (en) | 2010-04-15 |
Family
ID=26212970
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15812102A IL158121A0 (en) | 2001-04-10 | 2002-04-09 | 5-membered heterocycles, preparation and application thereof as medicaments |
IL158121A IL158121A (en) | 2001-04-10 | 2003-09-25 | 5-membered heterocycles, pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15812102A IL158121A0 (en) | 2001-04-10 | 2002-04-09 | 5-membered heterocycles, preparation and application thereof as medicaments |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1379514B1 (en) |
JP (1) | JP4422964B2 (en) |
KR (1) | KR100865809B1 (en) |
CN (1) | CN1284777C (en) |
AR (1) | AR036329A1 (en) |
AU (1) | AU2002307980B2 (en) |
BR (2) | BRPI0208703B1 (en) |
CA (1) | CA2443403C (en) |
CZ (1) | CZ304550B6 (en) |
DE (1) | DE60232959D1 (en) |
ES (1) | ES2328467T3 (en) |
HK (1) | HK1070055A1 (en) |
HU (1) | HU228192B1 (en) |
IL (2) | IL158121A0 (en) |
IS (1) | IS2724B (en) |
MX (1) | MXPA03009194A (en) |
MY (1) | MY142094A (en) |
NO (1) | NO326051B1 (en) |
NZ (1) | NZ528645A (en) |
PL (1) | PL211939B1 (en) |
RU (1) | RU2288224C2 (en) |
TW (1) | TWI248438B (en) |
WO (1) | WO2002083656A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI283577B (en) | 1999-10-11 | 2007-07-11 | Sod Conseils Rech Applic | Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof |
US7291641B2 (en) * | 1999-10-11 | 2007-11-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
CA2469228A1 (en) | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
MXPA05010945A (en) * | 2003-04-09 | 2005-11-25 | Japan Tobacco Inc | Heteroaromatic pentacyclic compound and medicinal use thereof. |
EP1470818B1 (en) * | 2003-04-25 | 2006-07-26 | Neuro3D | Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns |
FR2888116A1 (en) | 2005-07-08 | 2007-01-12 | Sod Conseils Rech Applic | THIAZOLE DERIVATIVES FOR TREATING DYSKINESIES |
EP1806819A1 (en) * | 2006-01-05 | 2007-07-11 | Constructions Electroniques + Telecommunications, en abrégé "C.E.+T" | Backup power system |
TW200848417A (en) * | 2007-02-22 | 2008-12-16 | Organon Nv | Indole derivatives |
MX337469B (en) * | 2011-10-26 | 2016-03-02 | Pfizer Ltd | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators. |
CN113831360A (en) * | 2021-09-10 | 2021-12-24 | 中钢集团南京新材料研究院有限公司 | Method for synthesizing 1-carbazole-boronic acid pinacol ester through amide ortho-oriented boronation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326770A (en) * | 1992-07-17 | 1994-07-05 | The Du Pont Merck Pharmaceutical Company | Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals |
AU4368996A (en) * | 1994-11-23 | 1996-06-17 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
WO1997013768A1 (en) * | 1995-10-11 | 1997-04-17 | Synthelabo | Oxazolidin-2-one derivatives, preparation method therefor and therapeutical use thereof |
EP0946587A2 (en) * | 1996-12-16 | 1999-10-06 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds |
FR2764889B1 (en) * | 1997-06-20 | 2000-09-01 | Sod Conseils Rech Applic | NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
IL135433A0 (en) * | 1997-10-06 | 2001-05-20 | Lilly Co Eli | Novel compounds useful as neuro-protective agents |
ATE229954T1 (en) * | 1998-06-12 | 2003-01-15 | Sod Conseils Rech Applic | BETACARBOLINE COMPOUNDS |
BR0009322A (en) * | 1999-03-26 | 2002-04-30 | Euro Celtique Sa | Pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles replaced with aryl and their use |
TWI283577B (en) * | 1999-10-11 | 2007-07-11 | Sod Conseils Rech Applic | Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof |
-
2002
- 2002-03-26 TW TW091105848A patent/TWI248438B/en not_active IP Right Cessation
- 2002-04-05 MY MYPI20021232A patent/MY142094A/en unknown
- 2002-04-09 BR BRPI0208703-0A patent/BRPI0208703B1/en unknown
- 2002-04-09 ES ES02761921T patent/ES2328467T3/en not_active Expired - Lifetime
- 2002-04-09 JP JP2002581412A patent/JP4422964B2/en not_active Expired - Fee Related
- 2002-04-09 CN CNB02807937XA patent/CN1284777C/en not_active Expired - Fee Related
- 2002-04-09 HU HU0303799A patent/HU228192B1/en not_active IP Right Cessation
- 2002-04-09 CZ CZ2003-3054A patent/CZ304550B6/en not_active IP Right Cessation
- 2002-04-09 CA CA2443403A patent/CA2443403C/en not_active Expired - Fee Related
- 2002-04-09 BR BRPI0208703-0A patent/BR0208703A/en not_active IP Right Cessation
- 2002-04-09 RU RU2003132471/04A patent/RU2288224C2/en not_active IP Right Cessation
- 2002-04-09 WO PCT/FR2002/001218 patent/WO2002083656A2/en active IP Right Grant
- 2002-04-09 IL IL15812102A patent/IL158121A0/en unknown
- 2002-04-09 PL PL372297A patent/PL211939B1/en unknown
- 2002-04-09 NZ NZ528645A patent/NZ528645A/en not_active IP Right Cessation
- 2002-04-09 KR KR1020037013243A patent/KR100865809B1/en not_active IP Right Cessation
- 2002-04-09 AU AU2002307980A patent/AU2002307980B2/en not_active Ceased
- 2002-04-09 MX MXPA03009194A patent/MXPA03009194A/en active IP Right Grant
- 2002-04-09 DE DE60232959T patent/DE60232959D1/en not_active Expired - Lifetime
- 2002-04-09 EP EP02761921A patent/EP1379514B1/en not_active Expired - Lifetime
- 2002-04-10 AR ARP020101330A patent/AR036329A1/en active IP Right Grant
-
2003
- 2003-09-25 IL IL158121A patent/IL158121A/en not_active IP Right Cessation
- 2003-10-08 IS IS6979A patent/IS2724B/en unknown
- 2003-10-09 NO NO20034524A patent/NO326051B1/en not_active IP Right Cessation
-
2005
- 2005-03-18 HK HK05102380A patent/HK1070055A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL158121A (en) | 5-membered heterocycles, pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments | |
MY145388A (en) | 5-membered heterocycle derivatives, production thereof and sue thereof as medicaments | |
CA2226039A1 (en) | Pyridylfuran and pyridylthiophene compounds | |
JP2020530446A5 (en) | ||
WO2002085901A8 (en) | Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists) | |
TWI265931B (en) | Composition and method for inhibiting platelet aggregation | |
CA2246839A1 (en) | Pharmaceutical compositions containing ampa receptor antagonists for treating dyskineslas associated with dopamine agonist therapy | |
SG45259A1 (en) | New thiazolybenzofuran derivatives processes for the preparation thereof and pharmaceutical composition comprising the same | |
CA2440042A1 (en) | Carboxamide derivatives as therapeutic agents | |
IL137266A0 (en) | Heterocyclic chemokine receptor antagonists and pharmaceutical compositions containing the same | |
SK112001A3 (en) | Agents with an antidepressive effect containing pramipexol and an additional antidepressant drug | |
BR0215777A (en) | Compound, method for preparing same, pharmaceutical composition for preventing and treating cardioischemia, cerebroischemia, cerebral arterial occlusion and for improving brain microcirculation, and use of the compound. | |
MY132473A (en) | Crystalline hydrochloride of (r)-(-)-2-<n-[4-(1,1- dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl>-chroman | |
WO2007109578A2 (en) | Substituted gamma lactams as prostaglandin ep2 agonists | |
WO2002078639A2 (en) | A method of treating proliferative diseases using eg5 inhibitors | |
TW340115B (en) | Triazine derivatives and pharmaceutical composition for hepatitis the invention relates to triazine derivatives and pharmaceutical composition for hepatitis | |
NZ320355A (en) | Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis | |
EP1201236A4 (en) | Medicinal compositions for preventing or treating viral myocarditis | |
JP2004516295A5 (en) | ||
JP2003514893A5 (en) | ||
IE912602A1 (en) | Use of heterocyclic amino-alcohol compounds for treatment of CNS diseases | |
PT838223E (en) | BRAIN EDEMA INHIBITOR | |
CA2733508A1 (en) | Compounds for the treatment of peripheral neuropathies | |
MX2008014921A (en) | Substituted pyrazinone derivatives for use as a medicine. | |
GEP20043240B (en) | Novel Thiazolidinedione Derivatives as Antidiabetic Agents, Methods for their Production and Pharmaceutical Composition Containing the Same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |